English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Serdexmethylphenidate (SDX) chloride (Cl) is a novel prodrug of d-methylphenidate (d-MPH). These studies evaluated the abuse potential of SDX Cl when administered orally, intranasally (IN), and intravenously (IV). Three randomized, double-blind, placebo- and active-controlled crossover studies were conducted in recreational drug users to evaluate the abuse-related effects of oral SDX (120 and 240 mg) vs. extended-release (ER) d-MPH (80 mg) and phentermine (60 mg); IN SDX (80 mg) vs. d-MPH (40 mg), and IV SDX (30 mg) vs. d-MPH (15 mg). Abuse-related subjective measures, pharmacokinetics, and safety were assessed. The primary endpoint of maximum (E max ) Drug Liking (DL) (0–100-point scale) was significantly higher following d-MPH vs. placebo, validating the studies. In the oral study, DL E max  was significantly higher following 80 mg ER d-MPH (E max  = 81.5) than 120 mg SDX (E max  = 62.8,  p  &lt; .001) and 240 mg SDX (E max  = 63.8,  p  = .006); and following 60 mg phentermine (E max  = 80.2) than 120 mg SDX ( p  = .0195), but not 240 mg SDX ( p  = .0665). DL E max  scores were significantly higher following IN d-MPH vs SDX (E max  = 93.2 vs. 71.0,  p  &lt; .0001) and following IV d-MPH vs. SDX (E max  = 84.3 vs. 56.6,  p  = .001). Intravenous SDX was non-inferior to placebo ( p  = .001) for DL E max . Secondary endpoints (e.g. Take Drug Again) were generally consistent with the primary endpoint. Maximal and overall d-MPH exposure was lower for SDX than d-MPH for all routes. Adverse events typical of stimulants were more frequent with d-MPH than SDX. These findings indicate that the novel d-MPH prodrug, SDX, has lower abuse potential than d-MPH and support its classification as a C-IV controlled substance.

Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate